Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma
G Carlos, R Anforth, A Clements, AM Menzies… - JAMA …, 2015 - jamanetwork.com
Importance The cutaneous adverse effects of the BRAF inhibitors vemurafenib and
dabrafenib mesylate in the treatment of metastatic melanoma have been well reported. The
addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-
activated protein kinase pathway. The combination of dabrafenib with the MEK inhibitor
trametinib dimethyl sulfoxide (CombiDT therapy) increases response rate and survival
compared with a BRAF inhibitor alone. Clinical trials have suggested that CombiDT therapy …
dabrafenib mesylate in the treatment of metastatic melanoma have been well reported. The
addition of a MEK inhibitor to a BRAF inhibitor improves the blockade of the mitogen-
activated protein kinase pathway. The combination of dabrafenib with the MEK inhibitor
trametinib dimethyl sulfoxide (CombiDT therapy) increases response rate and survival
compared with a BRAF inhibitor alone. Clinical trials have suggested that CombiDT therapy …
